Truqap to treat breast cancer
Drug Name: Truqap Active Ingredient: capivasertib Indication: An AKT inhibitor used in combination with fulvestrant for the treatment of advanced HR-positive breast cancer Approval Date: 11/16/2023 Company: AstraZeneca More: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capivasertib-fulvestrant-breast-cancer